GlaxoSmithKline
-
23andMe Admits ‘Mining’ Your DNA Data Is Its Last Hope
23andMe is in a death spiral. Almost everyone who wants a DNA test already bought one, a nightmare data breach ruined the company’s reputation, and 23andMe’s stock is so close to worthless it might get kicked off the Nasdaq. CEO Anne Wojcicki is on a crisis tour, promising investors the company isn’t going out of…
-
Remarkable Drug Trial Ends With All 18 Patients Cancer-Free
A cancer treatment has shown astounding results in a small clinical trial. All of the treated patients, who had a specific form of mid-stage rectal cancer, have since experienced complete remission. Though the findings are based on a sample size of just 18 people, they could hold important implications for treating these particular cancers.
-
Apple’s Health Experiment Is Riddled With Privacy Problems
Pharmaceutical giant GlaxoSmithKline (GSK) has partnered with Apple on a new clinical study on rheumatoid arthritis. The study relies on an iPhone app to collect data about arthritic symptoms from users as they go about their daily lives. That sounds great at first glance, but how well will it protect your privacy?